The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.

Neoadjuvant chemotherapy has become standard therapy in the management of breast cancer patients with locally advanced disease with inoperable tumors and inflammatory breast cancer. Patients with earlier stage breast cancer and operable tumors may also benefit from treatment with neoadjuvant chemotherapy. Docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) is thought to be one of the most potent agents in the treatment of metastatic breast cancer and is therefore being investigated for its likely benefit in preoperative, neoadjuvant regimens.

[Sarcoidosis. Case report of a patient with isolated sarcoidosis of the breast].

The case of a 41-year-old woman with sarcoidosis of the breast without evidence of disease elsewhere is reported. The diagnosis was established histologically, and other causes of the sarcoid-like granulomatous lesions could be excluded.